Log in
Enquire now
‌

US Patent 10428319 Engineered Cas9 nucleases

Patent 10428319 was granted and assigned to Editas Medicine on October, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Editas Medicine
Editas Medicine
0
Current Assignee
Editas Medicine
Editas Medicine
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
104283190
Patent Inventor Names
Derek Cerchione0
Barrett Ethan Steinberg0
Date of Patent
October 1, 2019
0
Patent Application Number
160039670
Date Filed
June 8, 2018
0
Patent Citations Received
‌
US Patent 12110545 Methods of assessing nuclease cleavage
0
‌
US Patent 11713455 Enhanced selection of efficient targeted genome manipulating agents
0
‌
US Patent 11866726 Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
0
‌
US Patent 11499151 Methods and systems for analyzing guide RNA molecules
Patent Primary Examiner
‌
Robert B Mondesi
0
Patent abstract

The present disclosure relates to Cas9 nuclease variants and methods of producing and using such variants.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10428319 Engineered Cas9 nucleases

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.